DK1003534T3 - Reovirus til behandling af neoplasi - Google Patents

Reovirus til behandling af neoplasi

Info

Publication number
DK1003534T3
DK1003534T3 DK98940002T DK98940002T DK1003534T3 DK 1003534 T3 DK1003534 T3 DK 1003534T3 DK 98940002 T DK98940002 T DK 98940002T DK 98940002 T DK98940002 T DK 98940002T DK 1003534 T3 DK1003534 T3 DK 1003534T3
Authority
DK
Denmark
Prior art keywords
reovirus
neoplasia
treatment
neoplasm
pkr
Prior art date
Application number
DK98940002T
Other languages
English (en)
Inventor
Patrick W K Lee
James Strong
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DK1003534T3 publication Critical patent/DK1003534T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98940002T 1997-08-13 1998-08-12 Reovirus til behandling af neoplasi DK1003534T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/911,383 US6110461A (en) 1997-08-13 1997-08-13 Reovirus for the treatment of neoplasia
PCT/CA1998/000774 WO1999008692A1 (en) 1997-08-13 1998-08-12 Reovirus for the treatment of neoplasia

Publications (1)

Publication Number Publication Date
DK1003534T3 true DK1003534T3 (da) 2002-05-21

Family

ID=25430159

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98940002T DK1003534T3 (da) 1997-08-13 1998-08-12 Reovirus til behandling af neoplasi

Country Status (14)

Country Link
US (9) US6110461A (da)
EP (3) EP1003534B1 (da)
JP (1) JP4291884B2 (da)
AT (1) ATE213948T1 (da)
AU (1) AU731810B2 (da)
CA (1) CA2283280C (da)
DE (2) DE69804106T2 (da)
DK (1) DK1003534T3 (da)
ES (1) ES2157870T3 (da)
GR (1) GR20010300030T1 (da)
IL (1) IL131598A (da)
NZ (1) NZ337493A (da)
PT (1) PT1003534E (da)
WO (1) WO1999008692A1 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US20020147996A1 (en) * 2000-07-07 2002-10-10 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20020156039A1 (en) * 2000-07-07 2002-10-24 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
ES2445704T3 (es) * 2000-11-09 2014-03-04 Oncolytics Biotech Inc. Métodos para el tratamiento de trastornos celulares proliferativos
AU2002218087A1 (en) * 2000-11-20 2002-05-27 Oncolytics Biotech Inc. Method for optimally delivering virus to a solid tumor mass
WO2002042468A2 (en) 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
WO2002043647A2 (en) * 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
IL157304A0 (en) 2001-03-16 2004-02-19 Oncolytics Biotech Inc Method of extracting virus from cell culture
WO2003011230A2 (en) * 2001-08-03 2003-02-13 Board Of Regents, The University Of Texas System Modified reoviral therapy
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
CA2374388C (en) * 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) * 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
US7319001B2 (en) 2002-03-09 2008-01-15 Neurogenex Co., Ltd. High throughput system for producing recombinant viruses using site-specific recombination
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
EP1944035A1 (en) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
NZ536102A (en) * 2002-05-09 2008-01-31 Oncolytics Biotech Inc Oncolytic viruses, in particular reovirus, for reducing pain associated with proliferative disorders, particularly with the growth of a solid tumour mass
AU2003238008A1 (en) * 2002-06-12 2003-12-31 Temple University Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20060241178A1 (en) * 2002-12-30 2006-10-26 Immuneguard Llc Compositions and methods for treating lung cancer
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
ATE539162T1 (de) 2003-03-27 2012-01-15 Ottawa Hospital Res Inst Mutierte viren der vesikulären stomatitis und deren verwendung
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
CA2575591A1 (en) * 2003-08-08 2005-02-17 Yuji Shino A pharmaceutical composition for treatment of cancers
DK1668025T3 (da) * 2003-09-26 2014-08-25 Novartis Ag Seneca Valley-virusbaserede præparater og fremgangsmåder til behandling af sygdom
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
US20050137152A1 (en) * 2003-12-19 2005-06-23 Danny Cheung Reovirus for the prevention of neoplasia
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
DK1984007T3 (da) * 2006-02-13 2015-12-07 Oncolytics Biotech Inc Anvendelse af lavdoseret lokal immunsuppression til forstærkning af onkolytisk viral terapi
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
SG191602A1 (en) * 2007-03-12 2013-07-31 Oncolytics Biotech Inc Reoviruses having modified sequences
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
JP5944901B2 (ja) 2010-09-02 2016-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 水疱性口内炎ウイルス
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
AU2013204555A1 (en) * 2012-04-30 2013-11-14 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
WO2014204275A1 (ko) * 2013-06-21 2014-12-24 한국생명공학연구원 리오바이러스를 유효성분으로 함유하는 혈관신생 억제용 조성물
ES2796950T3 (es) 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
KR20230012484A (ko) * 2020-05-20 2023-01-26 바이로큐어 주식회사 암 예방 또는 치료용 약학적 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
PT70556A (en) * 1978-12-20 1980-01-01 Gist Brocades Nv Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
US4559229A (en) * 1982-07-20 1985-12-17 Research Foundation Avian proventriculitis vaccine
CA2045129A1 (en) * 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
WO1990011765A1 (en) * 1989-04-11 1990-10-18 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
DK0689447T3 (da) * 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
US5525342A (en) * 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US5853716A (en) * 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
WO1998008541A1 (en) 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
ES2445704T3 (es) * 2000-11-09 2014-03-04 Oncolytics Biotech Inc. Métodos para el tratamiento de trastornos celulares proliferativos
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
PT1505993E (pt) * 2002-05-10 2012-05-15 Oncolytics Biotech Inc Sensibilização de células neoplásicas a terapia de radiação com vírus oncolíticos
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
CA2825762A1 (en) * 2005-08-31 2007-03-08 Oncolytics Biotech Inc. Method for enhancing anti-neoplastic activity of an oncolytic virus using modified dendritic cells
SG191602A1 (en) * 2007-03-12 2013-07-31 Oncolytics Biotech Inc Reoviruses having modified sequences

Also Published As

Publication number Publication date
EP1003534B1 (en) 2002-03-06
DE1003534T1 (de) 2001-08-23
DE69804106D1 (de) 2002-04-11
EP1213023A1 (en) 2002-06-12
US6261555B1 (en) 2001-07-17
US7300650B2 (en) 2007-11-27
US20010048920A1 (en) 2001-12-06
PT1003534E (pt) 2002-08-30
ATE213948T1 (de) 2002-03-15
EP1003534A1 (en) 2000-05-31
JP4291884B2 (ja) 2009-07-08
ES2157870T1 (es) 2001-09-01
US20040265271A1 (en) 2004-12-30
AU8847198A (en) 1999-03-08
GR20010300030T1 (en) 2001-08-31
US20090110665A1 (en) 2009-04-30
US6344195B1 (en) 2002-02-05
US20090098089A1 (en) 2009-04-16
WO1999008692A1 (en) 1999-02-25
US7476382B2 (en) 2009-01-13
NZ337493A (en) 2000-12-22
IL131598A (en) 2005-03-20
IL131598A0 (en) 2001-01-28
US20020187125A1 (en) 2002-12-12
US6110461A (en) 2000-08-29
CA2283280A1 (en) 1999-02-25
EP1433483A1 (en) 2004-06-30
HK1028340A1 (en) 2001-02-16
ES2157870T3 (es) 2002-10-16
AU731810C (en) 1999-03-08
AU731810B2 (en) 2001-04-05
DE69804106T2 (de) 2002-08-14
US20050123513A1 (en) 2005-06-09
JP2002511886A (ja) 2002-04-16
US6576234B2 (en) 2003-06-10
CA2283280C (en) 2005-10-18

Similar Documents

Publication Publication Date Title
PT1003534E (pt) Reovirus para o tratamento de neoplasia
DE3650185D1 (de) Polarisierungslinse, undurchlässig für ultraviolette strahlung und blaues licht.
DK0428038T3 (da) Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE69102307D1 (de) Omeprazolezusammensetzung zur rektalen Anwendung.
IS5591A (is) Grunnmassaprótínsamsetningar til sáragræðslu
DK0467026T3 (da) Middel til farvning af hår og anvendelse af midlet
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
ES2181168T3 (es) Mezclas solidas a base de sulfonilureas y adyuvantes.
DE69510545D1 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
FI874166A7 (fi) 2',3'-dideoksisytidin-2'-eenin käyttö retroviruksilla infektoituneiden potilaiden hoitoon.
NO892665L (no) Fluorerte primaerbelysningspreparater, deres anvendelse ogfremstilling.
DK0508095T3 (da) Dentalmaterialer på grundlag af (meth)-acrylater
DK150604C (da) Analogifremgangsmaade til fremstilling af calciumoxaprozin
DK591787A (da) Anvendelse af 5-(substitueret phenyl)-oxa-zolidinonderivater til fremstilling af et til behandling af depressioner egnet laegemiddel
NO970185L (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
ATE356144T1 (de) Regulatorische/entfaltende peptide von ezrin
TR200001075T2 (tr) Tiamfenikol ve diklofenak içeren bileşimler.
ATE132500T1 (de) 24r-scymnol, herstellung und verwendung
NO904725L (no) Sammenfoeyede, aminmodifiserte polyalkylenoksyder, fremstilling derav og anvendelse derav som emulsjonsspaltemidler.
BR9711960A (pt) Verapamil como um medicamento para o tratamento de angina
DK435089D0 (da) Anvendelse af zofenopril til behandling af rheumatoid arthritis
DK31889A (da) Anvendelse af cyclophilin som antiinflammatorisk og immunmodulerende middel.
MX9207461A (es) Soluciones de poli(sulfuro de arileno), procedimientos para su preparacion y su utilizacion.
BR0012380A (pt) 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples